Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Atezolizumab and Cobimetinib in PD-1/PD-L1 Inhibitor Resistant or Refractory Non-Small Cell Lung Cancer

NCT03600701 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT03600701
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03600701 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Atezolizumab and Cobimetinib in PD-1/PD-L1 Inhibitor Resistant or Refractory Non-Small Cell Lung Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 29, 2018
Completion date
October 3, 2026
Enrollment
53 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic lung non-small cell carcinoma, recurrent lung non-small cell carcinoma, refractory lung non-small cell carcinoma, stage iv lung cancer ajcc v8